Category Archives: Federal Budget
Launch sequencing and the 5% F1 price cut: strategic considerations for your patented medicine
Achieving optimal prices for patented medicines is a critical issue close to the heart of the pharmaceutical industry. The 2015/16 Federal Budget introduced new savings measures with implications for prices of patented medicines in Australia. In the current environment, launch … Continue reading
Senate Estimates point to possible MRFF clinical trial funding
News that the Government is interested in using disbursements from the A$20 billion Medical Research Future Fund (MRFF) to invest in clinical trials is positive for the Australian life sciences R&D sector. There has been extensive speculation about whether the … Continue reading
$20bn investment into medical research – means what?
The Australian Government’s recent announcement of a AUD$20 billion Medical Research Future Fund (MRFF), the largest medical research fund in the world, has been something of a welcome surprise to the Australian medical research community. Australia has always been strong … Continue reading
Top 5 – Health in the 2014 Budget
Health has featured strongly in the Abbott Government’s first budget, but not as expected… 1. No PBS Pricing Reforms The anticipated PBS pricing reforms were absent in last week’s budget despite the recommendations of the Commission of Audit for the … Continue reading
PBS off the chopping block… for now
The pharmaceutical sector’s response to the Abbott Government’s first Budget seems to have been one of tentative collective relief, with the anticipated PBS pricing reforms conspicuously absent. However this relief may be short-lived as further PBS reforms may still proceed … Continue reading
Budget 2013 – A Bland Budget
On Tuesday 14th May, Treasurer Wayne Swan delivered what many have called a ‘safe’ budget. Opting not to use his time to outline a range of pre-election sweeteners, the government chose to defend its deficit position in a bland budget that focussed on Labor’s two legacy items – Gonski and the NDIS. Continue reading
Budget 2013 – A changing PBS operating environment
For many Eye Spy readers, hearing no price related changes to the PBS was the best possible outcome of the 2013 Budget. A momentary sigh of relief, but upon closer inspection we see that the operating environment for medicines is changing in Australia despite repeated calls for certainly and predictability. Continue reading
Top 5 – Health Items in the 2013 Budget
We look a little deeper into the Budget papers to find the Top 5 Health announcements. Continue reading
Election Watch – Business as Usual
This week is the last parliamentary sitting week in Canberra and the last chance for industry to state its case on the hill before the long Christmas break. So, what can the industry expect during this last sitting week? Are we any closer to an election? Does the US result give us anything to go by? Continue reading
Election Watch – The Question of When
A new feature of Eye Spy, ‘Election Watch’ will keep a close eye on Canberra in the lead up to the next election. We will follow the key decision-makers and look at the critical issues affecting the Australian medicines industry and the broader health sector. Continue reading
